Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
180 Patient Trial of 2nd Generation Oxazolidinone Enrolls in Four Months
“The rapid enrollment in this trial is not only a testimony to the diligence and competence of our clinical investigators and colleagues, but is also an indicator of the increasing prevalence of bacterial infections caused by MRSA in our hospitals and communities and the potential for an oral drug to confront this epidemic,” said
“Having initiated Phase 1 testing of torezolid in January of 2008, it is very encouraging to have advanced the program through Phase 2 enrollment in approximately one year,” said
About Trius Therapeutics
Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company’s lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R), the only marketed antibacterial drug of the oxazolidinone class. Trius has licensed worldwide rights outside of Korea to torezolid from Dong-A Pharmaceuticals. Trius’ pipeline includes two preclinical programs with lead candidates being developed to treat serious infections caused by Gram-negative bacterial pathogens. For more information, visit www.triusrx.com.
SOURCE Trius Therapeutics, Inc.